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Abstract 
We describe the Prognostic factors for Mortality in prostate cancer (ProMort) study, and use 
it to demonstrate how weighted likelihood method can be used in nested case-control 
studies to estimate both relative and absolute risks in the competing-risks setting. ProMort is 
a case-control study nested in the National Prostate Cancer Register of Sweden (NPCR), 
comprising 1,710 low- or intermediate-risk prostate cancer patients who died from prostate 
cancer (cases) and 1,710 matched controls. Cause-specific hazard ratios (HR) and cumulative 
incidence (CIF) of prostate cancer death were estimated in ProMort using weighted flexible 
parametric models and compared with the corresponding estimates from the NPCR cohort. 
We further draw 1,500 random nested case-control subsamples of NPCR and quantified the 
bias in the HR and CIF estimates. Finally, we compared the ProMort estimates with those 
obtained by augmenting competing risks cases, and by augmenting both competing risk 
cases and controls. The HRs of prostate cancer death estimated in ProMort were 
comparable to those in NPCR. The HRs of dying from other causes were biased, which 
introduced bias in the CIFs estimated in the competing risks setting. When augmenting both 
competing risk cases and controls, the bias was reduced.  
 
Keywords: Absolute risk; Cumulative incidence function; Flexible parametric survival model; 
Inverse probability weighting; Nested case-control study; Weighted partial likelihood 
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Prostate cancer is one of the most common male cancers, with an estimated >1.1 million 
newly diagnosed men worldwide each year (1). In the current era of opportunistic prostate-
specific antigen (PSA) screening, up to 80% of prostate cancer patients have localized disease 
(2, 3). The 10-year prostate cancer-specific mortality among men with localized disease 
varies from 5% to 29% depending on risk category (4). While radical treatment is generally 
recommended in high-risk disease, treatment choice for men with low- or intermediate-risk 
disease is a clinical dilemma (5). Treatment side effects must be balanced against the risk of 
dying from competing events and the risk of dying from prostate cancer, and traditional 
clinicopathological prognostic factors, such as Gleason score, tumor stage and PSA at 
diagnosis, are insufficient to identify those who may benefit from treatment. Hence, there is 
a strong clinical need to identify additional molecular prognostic factors. However, 
identifying molecular prognostic markers among men with low- or intermediate risk prostate 
cancer is challenging. Due to the low long-term disease-specific mortality in these patients, 
unfeasibly large tissue repositories with extensive follow-up are needed to identify and 
validate novel molecular prognostic markers.  
 
The nested case-control study design and other cost-effective cohort subsampling 
techniques have been developed for the rare-event setting (6, 7). In these studies, relative 
rather than absolute risks are typically estimated. Estimates of absolute risk are however 
essential if a prediction model is to be clinically useful. Since the late 90s, different methods 
for unbiased and efficient estimation of absolute risks in nested case-control setting have 
been developed (8-14), and extened to the competing risks setting (10, 15-16). These 
methods are still underused in clinical epidemiological practice and there are very few 
examples of their practical application.  
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We have used the National Prostate Cancer Register of Sweden (NPCR), a well-defined 
cohort of virtually all prostate cancer patients in Sweden since 1998, to design and conduct a 
nested case-control study (ProMort). The primary aim of ProMort is to identify a tissue-
based, molecular signature of lethal prostate cancer for men with low- or intermediate-risk 
prostate cancer and to develop a clinically useful prognostic model predicting the individual 
risk of dying from prostate cancer.  
 
In this paper, we describe the ProMort study and provide a practical demonstration of how 
relative risks of prostate cancer death can be estimated using the weighted likelihood 
method (11). We further estimate the absolute risks of prostate cancer death in the 
presence of competing risks by also modelling the relative risks of death from other causes 
using the same method. Since in the ProMort study, cases who died from other causes and 
their corresponding controls have not been selected using standard incidence density 
sampling (contrary to what was done for cases who died from prostate cancer), the 
estimates of the absolute risks of prostate cancer death may be biased to the extent to 
which the relative risks of death from other causes are biased. Hence we explore the 
magnitude of this bias and we compare our estimates with those obtained by augmenting 
competing risks cases (16), i.e., cases who died from causes other than prostate cancer, and 
both competing risk cases and corresponding controls (17). We also provide a practical 
description, including Stata programming code, of absolute risks estimation in the presence 
of competing risks in nested case-control studies. 
 
METHODS 
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Study population 
The National Prostate Cancer Register of Sweden (NPCR), The NPCR includes incident cases 
of prostate cancer in Sweden since 1998 and covers 98% of all prostate cancers registered in 
the Swedish National Cancer Register, to which reporting is mandatory by law (18, 19). 
Detailed descriptions of NPCR have been published previously (18, 20). In short, NPCR 
contains detailed information on mode of detection (PSA-screening, lower urinary tract 
symptoms, other), clinical TNM stage, biopsy tumor differentiation (Gleason score or WHO 
grade), serum PSA level at diagnosis and planned primary treatment within 6 months of 
diagnosis (conservative (active surveillance or watchful waiting), curative (radical 
prostatectomy or radiotherapy) and non-curative treatment (primary androgen deprivation 
therapy)). Since 2007, additional information regarding the biopsy procedure (number of 
cores taken at biopsy, number of positive cores, total length of all biopsy cores and 
combined length of cancer in all cores), prostate volume, curative treatment (type of 
prostatectomy, type of primary radiotherapy and neoadjuvant hormone therapy) and 
postoperative Gleason score has been reported to NPCR. Vital status is updated annually by 
linkage to the Swedish Population Register. Date and cause of death, coded according to 
ICD-10, are obtained through linkage to the Swedish Cause of Death Register. Prostate 
cancer specific death is defined as death where prostate cancer was coded as “underlying 
cause of death” and has been shown to be reliable, especially for localized disease (21, 22).  
 
ProMort, ProMort is a case-control study nested among all men in NPCR diagnosed with low- 
or intermediate-risk prostate cancer between January 1, 1998 and December 31, 2011. We 
defined low- or intermediate-risk prostate cancer as a clinical tumor stage T1-T2, Gleason 
score ≤7 (or WHO grade 1 when information on Gleason grade was missing), serum PSA <20 
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ng/mL and no signs or non-assessed status of lymph node (N0 or Nx) or distant (M0 or Mx) 
metastases. At the time of linkage, follow-up was available until December 31, 2012. Among 
around 130,000 men in NPCR, 57,952 men fulfilled these criteria. Emigration occurred only 
among 0.23% men in NPCR and was not accounted for in the present analyses. We selected 
as cases all men who died from prostate cancer during follow-up (n=1,735), and randomly 
selected one control for each case, matched on year and hospital of diagnosis. The control 
had to be alive at the date of death of the respective case. This sampling scheme is often 
referred to as incidence-density sampling. Cases without an eligible control within the 
matching stratum (n=25) were excluded from the study. The final data set included 1,710 
cases and 1,710 matched controls. 
 
We abstracted information on age, clinical stage, Gleason score/WHO grade and PSA at 
diagnosis, as well as vital status and cause of death, from NPCR. Cause of death was coded as 
either “prostate cancer specific” or “other causes of death”. Tumor stage was coded as T1a, 
T1b, T1c and T2. We assigned Gleason score ≤6 to the 140 cases and 103 controls with WHO 
differentiation grade 1 but no information on Gleason score.  
 
Diagnostic slides were retrieved from the pathology wards across Sweden and scanned at 
40X using the Pannoramic 250 (3DHistech Ltd., Budapest, Hungary) digital slide scanner at 
Örebro University Hospital, Örebro, Sweden. After scanning, the images were uploaded to a 
specialized software based on the enhanced version of the Open Microscopy Environment 
Remote Objects (OMERO) platform (created and managed by the Centre for Advanced 
Studies, Research and Development in Sardinia (CRS4)) for visualizing, managing and 
annotating scientific image data (23). Once uploaded into the software, the slides are 
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reviewed by two independent genitourinary pathologists and scored according to the 2014 
International Society of Urological Pathology (ISUP) modification of Gleason grading system 
(24). Non-low/intermediate risk prostate cancer patients (i.e., Gleason score >7) are 
excluded from future main analyses.  
 
Due to the limited amount of tissue available for molecular analysis we have conducted two 
pilot studies to (i) determine the best performing DNA/RNA extraction kit in terms of the 
amount of tissue needed for the extraction, and the quality of the extracted DNA/RNA 
(manuscript in preparation) and (ii) estimate the number and thickness of slices that can be 
cut from the tissue blocks and the minimum amount of tissue (mm cancer) needed to 
extract sufficient amount of DNA/RNA for molecular analyses. Based on the outcome of 
these pilot studies and on a parallel systematic literature review, most promising molecular 
markers of lethal prostate cancer will be prioritized for the main tissue analyses. 
 
Statistical analyses  
In nested case-control studies, logistic regression (conditional or unconditional) is typically 
used to assess the association between the exposure and the outcome. When the interest 
also lies in absolute risk estimation, the baseline hazard function has to be estimated. Due to 
the disproportionate representation of controls in nested case-control studies, naïve 
estimates of the baseline hazard result in biased absolute risk estimates (8). However, the 
sampling probability of the controls can be estimated in the underlying population and used 
to adjust the contribution of controls. Different methods for calculating this probability have 
been proposed (10-13) and absolute risks estimation has been described in the context of 
the weighted partial likelihood approach, even in presence of a matched design (8, 9, 11, 
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12). In such analysis, matching is broken, cases and controls are weighted with an inverse of 
their marginal probability of being sampled, and unique individuals are pooled for analysis, 
keeping only one control record for controls who were selected more than once, and a case 
record for the control who later became a case (11).  
 
When competing events preclude the occurrence of the primary event of interest the 
situation is more complex. Several approaches for dealing with competing risks in the cohort 
(25-34) and in the case-control setting (10, 15-16, 35) have been proposed. Due to the 
method of control selection for ProMort, in this paper, we focus on the cause-specific 
hazards approach. When a subject is at risk of having K different events, the cause-specific 
hazard,	𝜆#(𝑡), denotes the instantaneous rate of event 𝑘 in subjects who are still alive at the 
time 𝑡 and can be defined as:  
𝜆#(𝑡) = lim∆-→/ 𝑃(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡,𝐾 = 𝑘|𝑇 ≥ 𝑡)∆𝑡  
The cumulative incidence function (CIF) for the event of interest 𝑘 (i.e., prostate cancer 
death), 𝐼#(𝑡), is a probability that a subject dies from the event 𝑘 at the time 𝑡 accounting 
for the fact that he can die from other cause(s) (i.e., death from other causes).  
𝐼#(𝑡) = 𝑃(𝑇 ≤ 𝑡|𝐾 = 𝑘) = : 𝜆#(𝑢)	𝑒𝑥𝑝 ?−: A𝜆#(𝑣)𝑑𝑣D#EFG/ H-/ 𝑑𝑢 = : 𝜆#(𝑢)I𝑆#(𝑢)𝑑𝑢D#EF-/  
The CIF depends not only on the cause-specific hazard for the event of interest but also on 
the cause-specific hazard for the competing event(s) (26, 27).  
 
35In this paper, we compare the relative risks (i.e. the hazard ratios (HRs)) and the absolute 
risks (i.e. the CIFs) estimated in ProMort using inverse probability weighting approach to 
those estimated in NPCR. Then we use two alternative approaches to estimate the HRs and 
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CIFs. In the first approach, denoted “Method 1”, we augment both the competing risk cases, 
i.e. cases who died from other causes, and the corresponding controls according to the 
incidence density sampling principle (17). In the second approach, denoted “Method 2”, we 
augment only the competing risk cases (16). The main idea behind the two methods is the 
reuse of the controls, and the cases, selected for one endpoint as controls in the analysis of 
another endpoint with or without a new control selection. These two methods are 
extensions of the inverse probability weighting approach to nested case-control studies with 
more than one endpoint, including competing risks (16, 17).  
 
The inverse probability weighting methods have been described in the context of the partial 
likelihood (8, 9, 11, 12). Partial likelihood is used for the parameter estimation in the Cox 
proportional hazards model where the baseline hazard function does not depend on any 
parameters and is thus not estimated. Since we are interested in both the HRs and the CIFs, 
in this paper we use flexible parametric survival model (Royston-Parmar model) (28) instead 
of the Cox proportional hazards model. The flexible parametric model uses restricted cubic 
splines function of log time to model the baseline hazard function and its parameters are 
estimated by maximizing the full likelihood (29). In our analysis we use weighted full 
likelihood instead of the weighted partial likelihood. A detailed description of the step-by-
step analysis plan for the Method 1 and the Method 2 and a formal definition of the 
weighted full likelihood are presented in the Appendix A1. 
 
We calculated the weights as described by Kim (8), and fitted the flexible parametric model 
as described by Hinchliffe et al. (28). We selected the number of knots (1 internal knot, two 
degrees of freedom) and a suitable scale (proportional hazards) by minimizing the value of 
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Akaike and Bayes criterion (29). The number and location of the knots, however, are often 
not critical for a good fit of the model (28, 29). We simultaneously estimated cause-specific 
HRs and the corresponding 95% confidence intervals (CIs) of death from prostate cancer and 
death from other causes (29, 30), and obtained the CIFs by combing the cause-specific HR 
estimates (16, 17, 31).34 Time at risk was calculated from the date of diagnosis of prostate 
cancer until death or end of follow-up, whichever came first. 
 
Subject-matter knowledge and data availability were used to identify important predictors of 
prostate cancer death. Age (categorized into 10 year categories, ≤55, >55-65, >65-75, >75), 
PSA (<4, 4-10, ≥10), Gleason score (<7, 7) and clinical tumor stage (T1a, T1b, T1c, T2) at 
diagnosis were included in the prognostic model. As the matching was broken, we 
additionally adjusted for the matching variables (8, 13). To avoid unnecessary loss of power 
due to the large number of matching hospital strata, we joined all the hospitals in the same 
county and adjusted for county and year of diagnosis. These analyses were performed in 
both the full cohort and the nested case-control study samples.  
 
To further evaluate the method used for the relative and absolute risk estimation in 
ProMort, we drew 1,500 random nested case-control subsamples of NPCR using the same 
selection criteria as for ProMort (i.e. all cases and a random sample of matched controls). 
We calculated the absolute bias in HRs of death from prostate cancer and death from other 
causes on logarithmic scale as log(HRncc)-log(HRNPCR), where log(HRncc) indicates the log(HRs) 
estimated in the 1,500 subsamples and log(HRNPCR) indicates the log(HRs) estimated in NPCR. 
We also computed the absolute bias in CIFs of dying from prostate cancer at 5, 10 and 15 
years of follow-up. The absolute bias was defined as CIFncc-CIFNPCR , where CIFncc indicates 
12 
 
CIFs estimated in 1,500 subsamples and CIFNPCR indicates CIFs estimated in NPCR. In addition, 
we computed the coverage probability of the CIF 95% CIs estimated in the 1,500 subsamples 
at 5, 10 and 15 years of follow-up.  
 
All analyses were conducted in Stata (version 12.1, StataCorp, College Station, Texas, USA) 
and R statistical package (version 3.3.3, Institute for Statistics and Mathematics, Vienna, 
Austria, http://www.Rproject.org). 
 
RESULTS 
Baseline characteristics of all men with low- or intermediate-risk prostate cancer in NPCR 
(n=57,952) and ProMort (1,710 cases, 1,710 controls) are presented in Table 1. Low- and 
intermediate-risk prostate cancer patients who had died from prostate cancer/cases were 
on average older at diagnosis and had more aggressive tumors, including higher proportion 
of Gleason score 7, T2 stage tumors and higher mean PSA at diagnosis, compared to men 
who had not died from prostate cancer/controls. Around 24% of the men who died from 
prostate cancer had been treated with curative intent, compared to over 50% among men 
who did not die from prostate cancer. 
 
Results from the univariable analyses are presented in the Table 2. Age, PSA at diagnosis, 
Gleason score and clinical tumor stage were associated with the hazard of dying from 
prostate cancer with comparable point estimates in the NPCR and ProMort. Likewise, in the 
multivariable analyses, the risk of dying from prostate cancer increased with higher age, PSA, 
Gleason score and clinical tumor stage (Table 2). The point estimates in NPCR and ProMort 
were qualitatively similar, though in ProMort they were slightly overestimated for age and 
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clinical tumor stage, and underestimated for PSA (Figure 1). However, the mean absolute 
bias in the log(HRs) estimated in the 1,500 subsamples was generally close to zero for all 
covariates (Supplementary Table 1). The point estimates from the two alternative 
approaches were also comparable to the NPCR estimates (Supplementary Figure 1). The 
log(HRs) for death from other causes were generally biased for ProMort, with wide CIs 
(Figure 1). The mean absolute bias in the log(HRs) for other causes of death estimated in the 
1,500 subsamples was close to zero for clinical tumor stage, Gleason score and PSA, but not 
for age (-3.813, -0.118 and 0.118 for age ≤55, 65-75 and >75, respectively) (Supplementary 
Table 2). Contrary to the other covariates, the distribution of log(HRs) for age ≤55 category 
was not normal. Few subjects in the age ≤55 category died from other causes and when no 
cases who died from other causes were sampled the estimated log(HR) were extreme and 
not reliable. The log(HRs) for death from other causes were generally comparable in NPCR 
and Method 1 and 2 (Supplementary Figure 1). 
 
CIFs and 95% CIs of dying from prostate cancer for different combinations of risk factors at 5, 
10 and 15 years from diagnosis are presented in Figure 2. Overall, the cumulative incidence 
of prostate cancer death at 5, 10, and 15 years from diagnosis in ProMort and NPCR were 
similar. However, the bias in the ProMort estimates increased with age, and was especially 
notable at age >75 years (Figure 2). The mean absolute bias in the CIF estimates across the 
1,500 subsamples and across all combinations of covariates was less than 0.008 at all follow-
up times (Supplementary Table 3). However, it is worth noting that the mean absolute bias 
for age >75 years was 0.011, 0.025 and 0.025 at 5, 10 and 15 years of follow-up, respectively, 
while it was less than 0.004 across all other combinations of covariates at all follow-up times. 
The actual coverage probability averaged over all combinations of covariates was generally 
14 
 
conservative at over 97% at all follow-up times (Supplementary Table 3). However, for some 
combinations of covariates with the age>75 years, the coverage probability is less than the 
nominal value. CIFs estimated using the two alternative approaches, especially from the 
Method 1, were consistently similar to the estimates from the NPCR (Supplementary Figure 
2). 
 
DISCUSSION 
Novel prognostic markers of lethal prostate cancer are needed to aid risk assessment and 
decision making for low- and intermediate-risk prostate cancer patients. ProMort, a large 
case-control study nested in the well-annotated population-based cohort NPCR, aims to 
assess new molecular markers of lethal prostate cancer and develop a clinically useful model 
predicting prostate cancer mortality. ProMort cases and controls were selected using 
standard incidence-density sampling with the aim of estimating the relative risk of dying 
from prostate cancer. In this study, we have demonstrated that the relative risks of prostate 
cancer death estimated in ProMort are comparable to those in the full NPCR cohort. The 
estimates of relative risk of dying from other causes, on the other hand, are biased, and this 
introduces some bias in the absolute risks estimated in the competing risks setting. We have 
also shown that augmenting competing risks cases, or both the cases and the controls, 
reduces the bias in the relative risks of dying from other causes and thus also the bias in the 
absolute risks of dying from prostate cancer estimated in a competing risks setting.  
 
With 57,952 study participants and up to 15 years of follow-up, NPCR is, to the best of our 
knowledge, the largest cohort of men with low- or intermediate-risk prostate cancer, with 
detailed clinicopathological data, in the world. Even though death from prostate cancer 
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among low- and intermediate-risk prostate cancer patients is a rare event, our sample size is 
sufficient to study prostate cancer specific mortality as the main outcome. One of the 
limitations of NPCR is that all data are collected through routine clinical work and no central 
histopathological review is conducted (20). Furthermore, information on additional 
histopathological characteristics, potentially useful for predicting lethal prostate cancer, 
such as primary and secondary Gleason grade pattern, length of cancer or percentage of 
biopsy core positivity, is available in NPCR only for the subset of men diagnosed with 
prostate cancer from 2007 onwards (20). However, through digitalized diagnostic slide 
review we aim to obtain not only centrally re-assigned Gleason score and minimize bias due 
the changes in the Gleason scoring system over time and inter-pathologist variability, but 
also information on these additional histopathological characteristics for all cases and 
controls included in ProMort.  
 
Development of prognostic models and prediction of the absolute risk of a disease are 
traditionally carried out in cohort studies. However, in many chronic diseases the outcome 
of interest is rare to the extent that cohort studies become unfeasible, and the nested case-
control design may be a viable and cost-effective alternative. Methods for unbiased and 
efficient estimation of absolute risks in nested case-control studies were developed in the 
late 90s (10, 12). However, even though recent studies have confirmed their feasibility (8, 9, 
11, 13), these methods are still underused in clinical epidemiological practice. In this study, 
we analyzed a real-life nested case-control data using inverse probability weighting method 
proposed by Samuelson (12), which is easily implemented in the standard statistical 
software (Stata code is available in Appendix A2). The absolute risks estimated using the 
inverse probability weighting method are shown to be precise in the matched design, even 
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when fine matching is used (11). Furthermore, it has been shown that controls can be re-
used to make valid inferences on secondary, non-exclusive, outcomes (32, 33), and the 
extensions to the competing risk setting have been developed (15-16). It is important to 
note that we did not explore other approaches for estimating absolute risks in the 
competing risk setting, such as dealing with a nested case-control study as a missing data 
problem (17) and the approach based on subdistribution hazards (34, 3535). We preferred 
to model the cause-specific hazards as their interpretation is easier when compared to the 
subdistribution hazards, and proportionality assumed on the hazard scale is mathematically 
not satisfied on subdistribution hazard scale (36). 
 
ProMort was designed to provide unbiased estimates of the cause-specific HRs of dying from 
prostate cancer. We show that the HRs estimated in ProMort were comparable with the 
estimates derived from the full cohort (NPCR) and the absolute bias over 1,500 subsamples 
of NPCR was close to zero (Supplementary Table 1). On the other hand, the HRs of dying 
from other causes estimated in ProMort were biased. However, the absolute bias over 1,500 
subsamples was close to zero for PSA, clinical tumor stage and PSA, but it was larger for age, 
especially age ≤55 years (Supplementary Table 2). As estimates of CIF for death from 
prostate cancer depend on both cause-specific hazards, the CIFs estimated in ProMort, 
although generally similar to CIFs estimated in NPCR, show some bias, especially for age >75 
years. Similarly, the absolute bias in CIFs over 1,500 subsamples of NPCR and across all 
covariate combinations is close to zero at 5, 10 and 15 years after diagnosis and average 
coverage probability is conservative at all follow-up times. However, for age >75 years, the 
bias in CIF estimates increases and the coverage probability decreases. Alternative 
approaches with augmented competing risk cases (16), and especially with augmented 
17 
 
competing risk cases and controls (17), resulted in less biased CIF estimates. For ProMort, 
where cases and controls were sampled to gain efficiency, we therefore decided to use a 
two-step approach. First, we will use the current data to identify promising molecular 
markers, and then, if necessary, we will replicate the CIF estimates under the Method 1 or 
Method 2 sampling scheme. 
 
5. Conclusion 
To the best of our knowledge, ProMort is the world’s largest series of lethal low- and 
intermediate-risk prostate cancer patients and constitutes a valid setting for identification of 
clinically relevant prognostic biomarkers for men with low- and intermediate-risk prostate 
cancer. By comparing the predictive models developed in the case-control data with those 
developed in the underlying cohort, we have demonstrated that accurate estimates of the 
relative risks of dying from prostate cancer can be estimated in ProMort. However, in the 
competing risks setting, nested case-control studies with augmented competing risks cases 
and controls provide more valid absolute risks estimates.  
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Figure 1. Logarithm of the cause-specific hazard ratios and 95% confidence intervals of the 
risk of dying from prostate cancer and other causes estimated in NPCR and in ProMort, 
Sweden, 1998-2011. Reference categories (age >55-65, PSA <4, Gleason score <7, clinical 
tumor stage T1c) and estimates for the matching variables (year and county of diagnosis) are 
not shown in the figure. 
PSA, prostate-specific antigen; log(HR), Logarithm of the hazard ratio; NPCR, National 
Prostate Cancer Register of Sweden 
 
Figure 2. Cumulative incidence function and 95% confidence intervals of dying from prostate 
cancer for men with low- and intermediate-risk prostate cancer in NPCR and in ProMort, 
Sweden, 1998-2011. CIFs were estimated for different combinations of risk factors at 5 (A), 
10 (B) and 15 (C) years of follow-up. Year (2004) and county (Västra Götaland) of diagnosis 
were kept constant. 
NPCR, National prostate cancer register of Sweden; T, Clinical tumor stage; GS, Gleason 
score; PSA, prostate-specific antigen 
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Table 1. Baseline Characteristics of Low- and Intermediate-Risk Prostate Cancer Patients in 
NPCR and of Cases and Controls in ProMort, Sweden, 1998-2011 
 NPCR ProMort 
Dead from PCa 
(n=1,735) 
Not dead from PCa 
(n=56,217) 
Cases 
(n=1,710) 
Controls 
(n=1,710) 
n % n % n % n % 
Year of diagnosis 
1998-2000 591 34.06 5,377 9.56 578 33.80 578 33.80 
2001-2004 751 43.29 14,339 25.51 741 43.33 741 43.33 
2005-2008 336 19.37 19,239 34.22 334 19.53 334 19.53 
2009-2011 57 3.29 17,262 30.71 57 3.33 57 3.33 
Age at diagnosis (mean, SD) 
 73.75 (7.75) 67.21 (7.99) 73.73 (7.75) 67.62 (7.76) 
Age at diagnosis (10-year categories) 
≤55 29 1.67 3,168 5.64 29 1.70 80 4.68 
>55-65 205 11.82 19,731 35.10 200 11.70 568 33.22 
>65-75 699 40.29 23,725 42.20 690 40.35 756 44.21 
>75 802 46.22 9,596 17.06 791 46.26 306 17.89 
Gleason score 
≤6 948 54.64 39,114 69.58 927 54.21 1328 77.66 
7 787 45.36 17,103 30.42 783 45.79 382 22.34 
Tumor stage 
T1 2 0.12 58 0.10 2 0.12 2 0.12 
T1a 76 4.38 2,829 5.03 75 4.39 119 6.96 
T1b 94 5.42 1,366 2.43 92 5.38 51 2.98 
T1c 534 30.78 33,104 58.89 521 30.47 854 49.94 
T2 1,029 59.31 18,860 33.55 1,020 59.65 684 40.00 
PSA (mean, SD)  
 10.36 (4.56) 7.99 (4.08) 10.36 (4.58) 8.77 (4.29) 
PSA 
<4 116 6.69 7,239 12.88 116 6.78 176 10.29 
4-9.9 754 43.46 33,659 59.87 740 43.27 933 54.56 
≥10 865 49.86 15,319 27.25 854 49.94 601 35.15 
Follow-up time in years (median, 25th and 75th percentile) 
 5.87 (3.58-8.57) 5.55 (3.08-8.35) 5.86 (3.59-8.51) 9.86 (7.56-12.09) 
Cause of censoringa, b 
Death           
Prostate cancer 1,735 100.00   1,710 100.00 80 4.68 
Other causes   7,968 14.17   262 15.32 
Administrativec   48,249 85.83   1,368 80.00 
Initial treatment 
Conservative 798 46.80 20,804 37.87 785 46.70 648 38.53 
Curative 412 24.16 29,653 53.98 407 24.21 849 50.48 
Non-curative 495 29.03 4,476 8.15 489 29.09 185 11.00 
Missing 30  1,284  29  28  
Abbreviations: NPCR, National prostate cancer register; PCa, prostate cancer; SD, standard deviation; 
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PSA, prostate-specific antigen 
a No right censoring in the study was assumed due to the very low percentage (0.23%) of loss to follow-
up  
b For ProMort controls, censoring refers to the follow-up after the sampling into the ProMort study  
c Administrative censoring was on December 31, 2012 
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Table 2. Univariable and Multivariable Flexible Parametric Proportional Hazards Model of the 
Risk of Dying From Prostate Cancer Among Low- and Intermediate-Risk Prostate Cancer 
Patients in the NPCR and in the ProMort, Sweden, 1998-2011 
 NPCR ProMorta 
Univariable Multivariable Univariable Multivariable 
HRb 95% CI HRb 95% CI HRb 95% CI HRb 95% CI 
Age (10-year categories) 
≤55 0.92 0.62, 1.36 0.99 0.67, 1.47 1.03 0.64, 1.66 1.07 0.63, 1.82 
>55-65 1.00  1.00  1.00  1.00  
>65-75 2.87 2.46, 3.36 2.56 2.19, 2.99 3.12 2.53, 3.86 2.90 2.32, 3.63 
>75 9.15 7.84, 10.68 7.02 5.97, 8.25 10.34 8.23, 13.00 8.06 6.26, 10.38 
PSA (ng/mL) 
<4 1.00  1.00  1.00  1.00  
4-9.9 1.40 1.15, 1.70 1.28 1.05, 1.57 1.22 0.92, 1.63 0.99 0.72, 1.35 
≥10 2.91 2.39, 3.54 1.83 1.48, 2.25 2.60 1.94, 3.48 1.43 1.03, 1.98 
Gleason score 
≤6 1.00  1.00  1.00  1.00  
7 2.99 2.71, 3.29 2.17 1.95, 2.40 3.04 2.56, 3.59 2.23 1.84, 2.72 
Tumor stagec 
T1a 1.21 0.95, 1.55 0.96 0.75, 1.24 1.40 1.00, 1.95 0.79 0.52, 1.20 
T1b 2.87 2.29, 3.60 1.67 1.32, 2.12 3.84 2.59, 5.70 2.25 1.49, 3.41 
T1c 1.00  1.00  1.00  1.00  
T2 2.61 2.35, 2.91 1.74 1.56, 1.95 3.00 2.54, 3.54 1.83 1.51, 2.23 
Abbreviations: NPCR, National prostate cancer register; HR, hazard ratio; 95% CI, 95% 
confidence intervals; PSA, prostate-specific antigen 
a Duplicate observations (n=150) are excluded from the analysis 
b Additionally adjusted for year and county of diagnosis 
c Subjects with non-sub-classified T1 stage (NPCR: n=60, 2 cases and 58 controls; ProMort: n=3, 
2 cases and 1 control) are excluded from the analysis 
 
 
 
